Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
2.110
+0.060 (2.93%)
At close: Nov 21, 2024, 4:00 PM
2.120
+0.010 (0.47%)
After-hours: Nov 21, 2024, 4:31 PM EST
Allogene Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2017 |
| Cash & Equivalents | 51.24 | 83.16 | 61.9 | 173.31 | 183.35 | 175.13 | Upgrade
|
| Short-Term Investments | 240.33 | 365.54 | 455.42 | 283.99 | 644.56 | 355.41 | Upgrade
|
| Cash & Short-Term Investments | 291.56 | 448.7 | 517.32 | 457.3 | 827.91 | 530.53 | Upgrade
|
| Cash Growth | -37.37% | -13.27% | 13.12% | -44.76% | 56.05% | 15.49% | Upgrade
|
| Other Receivables | 2.8 | 1.7 | 3.3 | 6 | 6.6 | 4.6 | Upgrade
|
| Receivables | 2.8 | 1.7 | 3.3 | 6 | 6.6 | 4.6 | Upgrade
|
| Prepaid Expenses | 10.05 | 8.72 | 8.2 | 8.02 | 10.62 | 9.44 | Upgrade
|
| Total Current Assets | 304.42 | 459.12 | 528.82 | 471.32 | 845.13 | 544.58 | Upgrade
|
| Property, Plant & Equipment | 135.3 | 163.18 | 196.43 | 181.02 | 160.14 | 100.94 | Upgrade
|
| Long-Term Investments | 111.82 | 3.65 | 79.47 | 370.18 | 207.95 | 63.21 | Upgrade
|
| Other Intangible Assets | - | - | - | - | - | 0.15 | Upgrade
|
| Other Long-Term Assets | 37.58 | 16.9 | 16.86 | 16.11 | 14.62 | 8.92 | Upgrade
|
| Total Assets | 589.12 | 642.84 | 821.58 | 1,039 | 1,228 | 717.8 | Upgrade
|
| Accounts Payable | 5.51 | 5.9 | 13.89 | 10.26 | 10.39 | 9.25 | Upgrade
|
| Accrued Expenses | 19.68 | 21.98 | 29.73 | 29.65 | 29.83 | 14.39 | Upgrade
|
| Current Portion of Leases | 7.39 | 6.78 | 6 | 3.2 | 2.97 | 1.68 | Upgrade
|
| Current Unearned Revenue | - | 0.09 | 0.1 | 0.42 | 38.99 | - | Upgrade
|
| Other Current Liabilities | - | 2.34 | 4.02 | 4.65 | 12.13 | 7.76 | Upgrade
|
| Total Current Liabilities | 32.57 | 37.08 | 53.73 | 48.17 | 94.32 | 33.08 | Upgrade
|
| Long-Term Leases | 85.14 | 88.35 | 95.12 | 69.93 | 50.81 | 51.35 | Upgrade
|
| Other Long-Term Liabilities | 3.07 | 5.18 | 5.85 | 4.13 | 3.08 | 4.35 | Upgrade
|
| Total Liabilities | 125.37 | 130.6 | 154.7 | 122.23 | 148.21 | 88.78 | Upgrade
|
| Common Stock | 0.21 | 0.17 | 0.14 | 0.14 | 0.14 | 0.12 | Upgrade
|
| Additional Paid-In Capital | 2,223 | 2,075 | 1,912 | 1,822 | 1,726 | 1,024 | Upgrade
|
| Retained Earnings | -1,760 | -1,562 | -1,235 | -903.35 | -646.34 | -396.12 | Upgrade
|
| Comprehensive Income & Other | 0.16 | -0.96 | -9.93 | -2.57 | 0.27 | 1.15 | Upgrade
|
| Shareholders' Equity | 463.75 | 512.23 | 666.88 | 916.41 | 1,080 | 629.02 | Upgrade
|
| Total Liabilities & Equity | 589.12 | 642.84 | 821.58 | 1,039 | 1,228 | 717.8 | Upgrade
|
| Total Debt | 92.52 | 95.12 | 101.12 | 73.13 | 53.78 | 53.03 | Upgrade
|
| Net Cash (Debt) | 199.04 | 353.58 | 416.2 | 384.17 | 774.13 | 477.51 | Upgrade
|
| Net Cash Growth | -46.03% | -15.05% | 8.34% | -50.37% | 62.12% | 12.37% | Upgrade
|
| Net Cash Per Share | 1.08 | 2.25 | 2.91 | 2.83 | 6.43 | 4.72 | Upgrade
|
| Filing Date Shares Outstanding | 209.67 | 169.09 | 144.5 | 142.75 | 140.65 | 124.91 | Upgrade
|
| Total Common Shares Outstanding | 209.5 | 168.64 | 144.44 | 142.62 | 140.47 | 124.27 | Upgrade
|
| Working Capital | 271.84 | 422.04 | 475.1 | 423.15 | 750.81 | 511.5 | Upgrade
|
| Book Value Per Share | 2.21 | 3.04 | 4.62 | 6.43 | 7.69 | 5.06 | Upgrade
|
| Tangible Book Value | 463.75 | 512.23 | 666.88 | 916.41 | 1,080 | 628.87 | Upgrade
|
| Tangible Book Value Per Share | 2.21 | 3.04 | 4.62 | 6.43 | 7.69 | 5.06 | Upgrade
|
| Machinery | 41.01 | 41.94 | 41.15 | 37.96 | 31.29 | 19.61 | Upgrade
|
| Construction In Progress | - | - | 0.03 | 0.04 | 68.94 | 12.39 | Upgrade
|
| Leasehold Improvements | 107.55 | 108.62 | 108.55 | 108.35 | 31.52 | 29.92 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.